Bcl-xl antisense oligonucleotides induce apoptosis and increase sensitivity of pancreatic cancer cells to gemcitabine

International Journal of Cancer

Volumn 94, Issue 2, 2001, Pages 268-274

  Xu, Zhong Wei ^a   Friess, Helmut ^a,b   Solioz, Marc ^a   Aebi, Stefan ^a   Korc, Murray ^a   Kleeff, Jörg ^a   Büchler, Markus W ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antisense; Apoptosis; Bcl; Pancreatic cancer

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; GEMCITABINE; PROTEIN BCL X;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL VIABILITY; CHEMOSENSITIVITY; CYTOTOXICITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BCL-X PROTEIN; BLOTTING, NORTHERN; BLOTTING, WESTERN; DEOXYCYTIDINE; DRUG SYNERGISM; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0035888180     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1447     Document Type: Article

References (71)

1. The molecular biology of apoptosis
2. Apoptosis and autoimmune disease
3. The role of the bcl-2/ced-9 gene family in cancer and general implications of defects in cell death control for tumorigenesis and resistance to chemotherapy
4. Apoptosis in the pathogenesis and treatment of disease
5. The Bcl-2 protein family: Arbiters of cell survival
6. The conserved N-terminal BH4 domain of Bcl-2 homologues is essential for inhibition of apoptosis and interaction with CED-4
7. Analysis of the structure, transcripts and protein products of bcl-2, the gene involved in human follicular lymphoma
8. BCL-2 family: Regulators of cell death
9. Prevention of programmed cell death of sympathetic neurons by the bcl-2 proto-oncogene
10. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B ceils
11. Bcl-x, bcl-2-related gene that functions as a dominant regulator of apoptotic cell death
12. Bcl-XL protects cancer cells from p53-mediated apoptosis
13. Bcl-xs gene therapy induces apoptosis of human mammary tumors in nude mice
14. Over-expression of Bcl-xL gene in human gastric adenomas and carcinomas
15. Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas
16. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis
17. Taxol and estramustine-induced modulation of human prostate cancer cell apoptosis via alteration in bcl-xL and bak expression
18. Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis
19. Kaposi's sarcoma tumor cells preferentially express Bcl-xL
20. Moderate activation of the apoptosis inhibitor bcl-xL worsens the prognosis in pancreatic cancer
21. Bax, but not bcl-2, influences the prognosis of human pancreatic cancer
22. Immunohistochemical analysis of Bcl-2, Bax, Bcl-X and Mcl-1 expression in pancreatic cancers
23. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: Correlations with in vitro and in vivo chemoresponses
24. Overexpression of Bax gene sensitizes K562 erythroleukemia cells to apoptosis induced by selective chemotherapeutic agents
25. Spontaneous and radiation-induced apoptosis in lung carcinoma cells with different intrinsic radiosensitivities
26. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB
27. BCL-2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy
28. Expression of bcl-xL can confer a multidrug resistance phenotype
29. The Bcl-xL and Bax-alpha control points: Modulation of apoptosis induced by cancer chemotherapy and relation to TPCK-sensitive protease and caspase activation
30. AGA technical review on the epidemiology, diagnosis and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association
31. Pancreatic carcinoma
32. C-Myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice
33. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice
34. Antisense oligodeoxyribonucleotide downregulation of bcl-2 gene expression inhibits growth of the low-grade non-Hodgkin lymphoma cell line WSU-FSCCL
35. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence
36. Induction of growth inhibition and apoptosis in pancreatic cancer cells by auristatin-PE and gemcitabine
37. Pharmacodynamics of immediate and delayed effects of paclitaxel: Role of slow apoptosis and intracellular drug retention
38. New colorimetric cytotoxicity assay for anticancer-drug screening
39. A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer
40. Treatment of duct carcinoma of the pancreas with the LH-RH analogue buserelin
41. Use of the comet test in the evaluation of multidrug resistance of human cell lines
42. Apoptosis induced by erythroid differentiation of human leukemia cell lines is inhibited by Bcl-XL
43. bcl-2, bax, bcl-XL and bcl-XS expression in normal and neoplastic ovarian tissues
44. Modulation of apoptosis by endogenous Bcl-xL expression in MKN-45 human gastric cancer cells
45. Antisense oligonucleotides as therapeutic agents
46. Strategy for designing specific antisense oligonucleotide sequences
47. Antisense inhibition and adeno-associated viral vector delivery for reducing hypertension
48. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma
49. Promise and problems of Bcl-2 antisense therapy
50. Studies on the mechanism of stabilization of partially phosphorothioated oligonucleotides against nucleolytic degradation
51. Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleotide phosphorothioate in rats after intravenous administration
52. Reduction of erbB2 gene product in mamma carcinoma cell lines by erbB2 mRNA-specific and tyrosine kinase consensus phosphorothioate antisense oligonucleotides
53. Oligodeoxyribonucleotide uptake in primary human hematopoietic cells is enhanced by cationic lipids and depends on the hematopoietic cell subset
54. Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease
55. Modulation of cell death by Bcl-XL through caspase interaction
56. Distinct sites of action of Bcl-2 and Bcl-xL in the ceramide pathway of apoptosis
57. Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c
58. Acceleration of apoptotic cell death after the cleavage of Bcl-XL protein by caspase-3-like proteases
59. Bax-induced caspase activation and apoptosis via cytochrome c release from mitochondria is inhibitable by Bcl-xL
60. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death
61. Regulation of Bcl-xl channel activity by calcium
62. Bcl-x(L) forms an ion channel in synthetic lipid membranes
63. Bcl-xL regulates apoptosis by heterodimerization-dependent and -independent mechanisms
64. The role of antiapoptotic Bcl-2 family members in endothelial apoptosis elucidated with anti-sense oligonucleotides
65. Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer
66. Apoptosis- and necrosis-inducing potential of cladribine, cytarabine, cisplatin and 5-fluorouracil in vitro: A quantitative pharmacodynamic model
67. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
68. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines
69. Bcl-2 overexpression results in reciprocal downregulation of Bcl-X(L) and sensitizes human testicular germ cell tumors to chemotherapy-induced apoptosis
70. Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated upregulation of bcl-xL
71. Isolation and characterization of an apoptosis-resistant variant of human leukemia HL-60 cells that has switched expression from Bcl-2 to Bcl-xL